Latest Strategy Changes News

Mustera Property Group reported a 45% revenue increase to $7.28 million for the half-year ending December 2025, driven by strong sales at its Forbes Residences project. Despite this growth, the company posted a net loss of $724,430, narrowing its deficit from the previous year as it advances its key North Fremantle development.

Peak Processing Limited reported a sharp 47.7% revenue drop and a 257.7% increase in losses for H1 2026, alongside a significant asset impairment and ongoing going concern concerns.

Yojee Limited reported a 9% revenue increase driven by software activities, while net losses widened due to accelerated investment in its MOSAIC platform and joint venture costs. The company maintains a robust cash balance and has strengthened its leadership ahead of a mid-2026 commercial launch.

Vmoto Limited reported an 18% revenue decline to $46.8 million and a $9.9 million net loss in FY25, while accelerating its transformation into a full-stack electric mobility solutions provider with new global partnerships and product innovations.

Pure Foods Tasmania reports a $6.85 million half-year loss, driven by a strategic operational reset and loan covenant breach, while showing signs of stabilisation and margin improvement.

Resolute Mining Limited reported a robust financial turnaround in 2025, posting a $126.7 million net profit driven by higher gold prices and cost efficiencies despite lower production volumes. The granting of the Doropo mining permit and strategic asset sales mark key milestones in its West African expansion.

ClearVue Technologies reported a 9% reduced half-year loss of $5.25 million, while pushing forward with significant advancements in its solar glass technology and expanding global licensing partnerships.

Argent BioPharma reported a significantly reduced half-year loss of A$2.9 million, progressing a strategic acquisition to bolster its CannEpil drug pipeline and securing up to A$11 million in new funding.

Recce Pharmaceuticals reported a doubling of its net loss for the half-year ended December 2025 amid significant progress in its anti-infective drug development and a substantial funding boost. The company is advancing Phase 3 trials and expanding its patent portfolio while managing financial pressures.

Michael Hill International reported a 3% rise in group sales and a 28.6% jump in comparable EBIT for the half-year ended December 2025, driven by strong performances across Australia, Canada, and New Zealand. Despite improved earnings and cash flow, the board has opted to withhold an interim dividend, signalling cautious optimism.

Vinyl Group Ltd has reported a robust 49% increase in revenue for the first half of FY26, alongside a significant reduction in net loss, driven by strategic acquisitions and AI integration.

Nexalis Therapeutics reported a widening loss of $1.83 million for 2025, reflecting increased investment in product development and marketing. Despite the loss, the company boosted its cash reserves through equity raises and borrowings.